|
Peter
McPhedran, MD
Emeritus Professor
of Laboratory Medicine and Internal Medicine
CB
462
203-688-2436
peter.mcphedran@yale.edu
AB
1958 Harvard
MD 1962 Harvard
Fellowship: Hematology, Yale 1968-1970
Platelet
dysfunction is routinely evaluated by platelet aggregation, among
other tests. At times an aspirin-like defect is identified which
seems not to be caused by medication, but by a congenital enzyme
deficiency affecting platelet arachidonic acid metabolism. We have
identified three patients with such deficiency patterns; collaborators
at the University of Texas have confirmed defective or absent platelet
cyclooxygenase enzyme in these three patients, using molecular probes(1).
There are three more patients with aspirin-like platelet defects
awaiting molecular studies. We need also to determine whether the
enzymopathy is confined to platelets, or is also present in other
somatic cells.
Epidemiologic
surveys of patients with prolonged bleeding time (123 cases and
normal controls) and with unexplained anemia (202 anemic patients)
have been carried out, and the relative frequency of causes of platelet
dysfunction and anemia defined in our population. These studies
should help to guide physicians in the efficient evaluation of bleeding
disorders and anemia.
Thrombotic
thrombocytopenic purpura is an aggressive hematologic disorder manifested
by platelet microthrombi in arterioles, which is often managed effectively
by plasmapheresis. Some patients tend to relapse, and may die during
relapses. The drug ticlopidine interferes with platelet function
by blocking the platelet surface receptor for fibrinogen. In our
hands, it has led to prolonged remissions in four patients with
relapsing TTP(2).
Red
cell distribution width, or RDW, a measure of anisocytosis, is generally
accepted as useful in selecting certain causes of anemia, such as
iron deficiency among microcytic patients, B12 and folate deficiency
among macrocytic patients, and major hemoglobinopathies among patients
with abnormal hemoglobin. However, the RDW has never been tested
prospectively in unselected patients. We have chosen a set of 100
patients with extreme abnormal RDWs (23 and higher, 5 s.d.s above
the mean) to determine whether these extreme values actually select
any specific disorders (compared to controls within RDWs less than
2 s.d.s from the mean).
- Matijevic-Aleksic
N, McPhedran P, Wu KW. Bleeding Disorder Due to Platelet Prostaglandin
H Synthase-1 (PGH-1) Deficiency. Brit J Haematol 92:212-217, 1996.
- McPhedran
P and Mukamal K. Ticlopidine for Relapsing TTP. Blood 84:80a,
1994.
|